Total Payments
$2.3M
2024 Payments
$445,038
Companies
23
Transactions
2,711
Medicare Patients
685
Medicare Billing
$79,170
Payment Breakdown by Category
Other$1.8M (77.5%)
Travel$305,828 (13.2%)
Consulting$154,036 (6.7%)
Food & Beverage$60,012 (2.6%)
Education$108.05 (0.0%)
Gifts$62.14 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.8M | 758 | 77.5% |
| Travel and Lodging | $305,828 | 1,025 | 13.2% |
| Consulting Fee | $154,036 | 57 | 6.7% |
| Food and Beverage | $60,012 | 868 | 2.6% |
| Education | $108.05 | 2 | 0.0% |
| Gift | $62.14 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $578,393 | 704 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $478,060 | 495 | $0 (2024) |
| Alkermes, Inc. | $292,433 | 319 | $0 (2024) |
| ITI, Inc. | $240,993 | 252 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $166,448 | 260 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $146,661 | 208 | $0 (2021) |
| Axsome Therapeutics, Inc. | $133,633 | 132 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $110,628 | 83 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $73,601 | 92 | $0 (2017) |
| PFIZER INC. | $48,554 | 90 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $445,038 | 415 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($110,628) |
| 2023 | $406,809 | 378 | ITI, Inc. ($135,009) |
| 2022 | $284,178 | 302 | Teva Pharmaceuticals USA, Inc. ($88,312) |
| 2021 | $230,810 | 242 | Teva Pharmaceuticals USA, Inc. ($72,166) |
| 2020 | $135,593 | 172 | Teva Pharmaceuticals USA, Inc. ($43,881) |
| 2019 | $271,090 | 357 | Teva Pharmaceuticals USA, Inc. ($82,178) |
| 2018 | $298,061 | 467 | Takeda Pharmaceuticals U.S.A., Inc. ($129,520) |
| 2017 | $237,913 | 378 | Takeda Pharmaceuticals America, Inc. ($73,601) |
All Payment Transactions
2,711 individual payment records from CMS Open Payments — Page 1 of 109
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $228.63 | General |
| 12/16/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Neurology | ||||||
| 12/13/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Neurology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,220.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,300.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/05/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $112.95 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Central Nervous System | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $122.73 | General |
| Category: Central Nervous System | ||||||
| 12/04/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Travel and Lodging | Cash or cash equivalent | $32.16 | General |
| Category: Central Nervous System | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,760.00 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/26/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $5.12 | General |
| Category: SCHIZOPHRENIA | ||||||
| 11/25/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/25/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Travel and Lodging | In-kind items and services | $989.95 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/25/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $107.53 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $113.20 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/20/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | In-kind items and services | $162.72 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $850.63 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $624.79 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Travel and Lodging | Cash or cash equivalent | $264.11 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $117.67 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,780.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $1,107.00 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 137 | 188 | $51,746 | $17,371 |
| 2022 | 5 | 135 | 190 | $44,749 | $15,529 |
| 2021 | 8 | 199 | 280 | $62,637 | $23,842 |
| 2020 | 6 | 214 | 281 | $61,109 | $22,429 |
Total Patients
685
Total Services
939
Medicare Billing
$79,170
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 59 | 61 | $23,912 | $7,713 | 32.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 41 | 60 | $13,560 | $5,406 | 39.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 34 | $9,588 | $2,673 | 27.9% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Facility | 2023 | 18 | 33 | $4,686 | $1,579 | 33.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 57 | 58 | $20,664 | $7,373 | 35.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 42 | $6,042 | $2,322 | 38.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 25 | $5,434 | $1,978 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 31 | $7,165 | $1,898 | 26.5% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Facility | 2022 | 15 | 21 | $2,932 | $1,043 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 11 | 13 | $2,512 | $915.50 | 36.4% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 52 | 52 | $16,536 | $6,589 | 39.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 35 | 73 | $14,746 | $5,806 | 39.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 33 | 62 | $13,702 | $4,168 | 30.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $5,070 | $2,042 | 40.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 19 | 31 | $4,340 | $1,725 | 39.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 14 | 15 | $2,985 | $1,442 | 48.3% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Facility | 2021 | 22 | 23 | $3,036 | $1,156 | 38.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 11 | 11 | $2,222 | $913.00 | 41.1% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2020 | 61 | 63 | $20,034 | $6,998 | 34.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 38 | 60 | $12,120 | $4,790 | 39.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 46 | 74 | $10,360 | $4,140 | 40.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 28 | 39 | $8,498 | $2,881 | 33.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $6,240 | $2,536 | 40.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 25 | 29 | $3,857 | $1,084 | 28.1% |
About Dr. Fred Romeo, MD
Dr. Fred Romeo, MD is a Psychiatry healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568403814.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fred Romeo, MD has received a total of $2.3M in payments from pharmaceutical and medical device companies, with $445,038 received in 2024. These payments were reported across 2,711 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.8M).
As a Medicare-enrolled provider, Romeo has provided services to 685 Medicare beneficiaries, totaling 939 services with total Medicare billing of $79,170. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Columbus, OH
- Active Since 06/09/2006
- Last Updated 03/27/2008
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1568403814
Products in Payments
- REXULTI (Drug) $578,671
- CAPLYTA (Drug) $351,621
- AUSTEDO (Drug) $332,068
- Trintellix (Drug) $212,231
- ARISTADA (Drug) $175,560
- LATUDA (Drug) $166,425
- Auvelity (Drug) $133,633
- LYBALVI (Drug) $98,607
- Austedo XR (Drug) $95,074
- CHANTIX (Drug) $48,554
- UZEDY (Drug) $46,216
- COBENFY (Drug) $11,202
- QUVIVIQ (Drug) $7,492
- SPRAVATO (Drug) $6,244
- Aristada 441 mg (Drug) $6,225
- Vyvanse (Drug) $5,677
- FANAPT (Drug) $4,585
- VYVANSE (Drug) $2,041
- SD809-TD (Drug) $744.21
- TRINTELLIX (Drug) $314.54
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Columbus
Michael Saribalas
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Kevin Ware, Md, MD
Psychiatry — Payments: $1.1M
Psychiatry $1.1M
Dr. Peter Zafirides, Md, MD
Psychiatry — Payments: $127,832
Psychiatry $127,832
Dr. Benjamin Roy, M.d, M.D
Psychiatry — Payments: $102,125
Psychiatry $102,125
Barbara Gracious, M.d, M.D
Psychiatry — Payments: $58,986
Psychiatry $58,986
Dr. Pavan Dontineni, M.d, M.D
Psychiatry — Payments: $32,829
Psychiatry $32,829